Boston Scientific Co. (NYSE:BSX) Shares Acquired by Sei Investments Co.

Sei Investments Co. increased its holdings in Boston Scientific Co. (NYSE:BSX) by 3.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,710,266 shares of the medical equipment provider’s stock after acquiring an additional 137,397 shares during the quarter. Sei Investments Co.’s holdings in Boston Scientific were worth $362,739,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Sierra Summit Advisors LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at $8,038,000. TD Asset Management Inc increased its holdings in shares of Boston Scientific by 10.7% in the 4th quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock valued at $93,417,000 after acquiring an additional 155,565 shares during the period. BI Asset Management Fondsmaeglerselskab A S grew its position in Boston Scientific by 225.6% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock valued at $7,237,000 after buying an additional 73,219 shares during the last quarter. BDF Gestion purchased a new position in Boston Scientific in the 2nd quarter valued at $3,570,000. Finally, Precision Wealth Strategies LLC purchased a new position in Boston Scientific in the 4th quarter valued at $956,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the transaction, the executive vice president now owns 40,188 shares of the company’s stock, valued at approximately $2,978,734.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 20,949 shares of company stock worth $1,627,877 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on BSX shares. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a research report on Thursday, July 25th. Truist Financial lifted their price objective on shares of Boston Scientific from $86.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Raymond James lifted their price objective on shares of Boston Scientific from $91.00 to $94.00 and gave the company a “strong-buy” rating in a research report on Wednesday, September 4th. Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 price objective on shares of Boston Scientific in a research report on Thursday, July 25th. Finally, StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, September 13th. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.38.

Boston Scientific Price Performance

Boston Scientific stock opened at $83.92 on Friday. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $84.89. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. The firm’s 50-day simple moving average is $78.72 and its 200 day simple moving average is $74.63. The firm has a market capitalization of $123.12 billion, a PE ratio of 70.52, a P/E/G ratio of 2.75 and a beta of 0.79.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The business had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. During the same period in the previous year, the firm earned $0.53 EPS. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, equities research analysts predict that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.